Earnings ·
Interpace Biosciences expects Q3 revenue of $10.1M-$10.4M
IDXGInterpace Biosciences, Inc.
Interpace Biosciences announced preliminary, unaudited third quarter 2026 revenue expected to range from $10.1 million to $10.4 million. This represents approximately 11% to 14% growth compared with the second quarter of 2026 and 15% to 18% year-over-year growth against the third quarter of 2025. The figures are preliminary, subject to closing procedures and independent review, and actual results may differ materially. Interpace Biosciences operates in the molecular diagnostics industry, providing specialized tests for personalized medicine.